Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum BioVaxys Technology Corp. C.BIOV

Alternate Symbol(s):  BVAXF

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical... see more

CSE:BIOV - Post Discussion

BioVaxys Technology Corp. > BIOV GET THE POPCORN NEW 52 WK LOW @175 SHORT MAKE MONEY
View:
Post by moneywagon on Jan 28, 2022 10:38am

BIOV GET THE POPCORN NEW 52 WK LOW @175 SHORT MAKE MONEY

KEEP the pressure shorts
Symbol Issue Name Shares Net Change Date
$BIOV.CN BIOVAXYS TECHNOLOGY CORP. 133,866 76,103 15 Jan 2022
$BIOV.CN BIOVAXYS TECHNOLOGY CORP. 57,763 -18,344 31 Dec 2021
$BIOV.CN BIOVAXYS TECHNOLOGY CORP. 76,107 -232,461 15 Dec 2021
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities